Synthetic Cannabinoids and Renal TransplantKim D, DiBianco JM*, Gordhan CG, Bairdain S and Melancon JK
Department of Urology, The Transplant Institute, George Washington University, U.S.A
- *Corresponding Author:
- John Michael DiBianco
Department of Urology, The Transplant
Institute George Washington University, USA
Tel: (202) 413- 1240
E-mail: [email protected]
Received date: January 31, 2017; Accepted date: March 22, 2017; Published date: March 25, 2017
Citation: Kim D, DiBianco JM, Gordhan CG, Bairdain S, Melancon JK (2017) Synthetic Cannabinoids and Renal Transplant. J Clin Case Rep 7:942. doi:10.4172/2165-7920.1000942
Copyright: © 2017 Kim D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,provided the original author and source are credited.
Synthetic cannabinoids, also known as ‘spice’ or ‘K2’, have recently increased in popularity as a drug of abuse among young adults. It has been associated with unexplained acute kidney injury and electrolyte abnormalities in otherwise healthy individuals. The mechanism of this phenomenon is not fully understood although some reports suggest that it may be potentially due to synthetic cannabinoids having increased potency causing an accumulation of harmful levels of toxicity. It is not understood if the use of this drug should preclude deceased donor renal transplantation and currently there are no reports on the use of K2’s effect on donor graft function. Herein, we summarize the first reported case of renal transplantation from a deceased donor in whom K2 was a known mortal factor and outline the similar abnormal graft functions of the two recipients.